Abstract Number: 978 • ACR/ARP Annual Meeting 2019
Light Mediated Therapeutics in Arthritis
Background/Purpose: Rheumatoid arthritis (RA) therapies are constrained by the failure to deliver sufficient quantities of drug to the inflamed site, systemic side effects, and the…Abstract Number: 603 • ACR/ARHP Annual Meeting 2018
Rheumatologists Beliefs in the Effectiveness of Other Methotrexate-Based Treatment Approaches May Explain the Low Use of Triple Therapy: A Bayesian Belief Elicitation
Background/Purpose: Triple therapy (MTX, sulphasalazine (SSZ), hydroxychloroquine (HCQ)) has evidence to support its use from randomized trials (RCTs) but is not commonly used. The objective…Abstract Number: 2353 • ACR/ARHP Annual Meeting 2018
Attitudes and Beliefs Regarding Methotrexate in Patients with Rheumatoid Arthritis: Results from Australian Rheumatology Association Database
Background/Purpose: To determine beliefs about methotrexate (MTX) in patients with Rheumatoid Arthritis (RA) in relation to views obtained from a range of information sources.Methods: RA…Abstract Number: 497 • ACR/ARHP Annual Meeting 2016
The Identification of an ACR Score with the Optimal Discriminatory Ability Between Treatments in Patients with Early and Established Rheumatoid Arthritis
Background/Purpose: In patients (pts) with rheumatoid arthritis (RA), the American College of Rheumatology (ACR)20 score was developed to best discriminate effective from placebo…Abstract Number: 1586 • ACR/ARHP Annual Meeting 2015
Weight Loss in Obese Rheumatoid Arthritis (RA) Patients Improves Disease Activity without Modifying RA Treatment
Background/Purpose: Obesity is recognized as a systemic, low-grade inflammatory state and the adipose tissue as an endocrine organ releasing pro-inflammatory cytokines. On the other hand,…
